Buprenorfina en el manejo de dolor por cáncer

María Catalina  Soto Niño

Autores/as

María Catalina Soto Niño Instituto Nacional de Cancerología

Palabras clave:

dolor oncológico, buprenorfina transdérmica, opioide

Resumen Autores/as Referencias bibliográficas Cómo citar

Resumen

Actualmente los opioides son el soporte del manejo farmacológico, en particular del dolor moderado a severo. En este sentido, es importante disponer de distintas formulaciones y vías de administración, aún más en el contexto del paciente oncológico. La buprenorfina tiene un bajo peso molecular, de alta potencia y liposolubilidad combinada a una favorable tolerabilidad y un bajo potencial de abuso. Por dichas razones la buprenorfina es ideal para aplicación transdérmica. La evidencia clínica disponible demuestra eficacia y seguridad en el empleo de la buprenorfina transdérmica en el tratamiento de dolor de moderado a severo en el paciente oncológico. Sin embargo, la buprenorfina no ha sido extensamente estudiada en ciertas poblaciones como otros opioides y se requieren nuevas investigaciones para definir el rol de esta en circunstancias clínicas específicas.

Biografía del autor/a

María Catalina Soto Niño, Instituto Nacional de Cancerología

Instituto Nacional de Cancerología. Bogotá, Colombia.

Referencias bibliográficas

Hanks GW. Cancer pain and the importance of its control. Anticancer Drugs. 1995;6 Suppl 3:14-7.

https://doi.org/10.1097/00001813-199504003-00003

World Health Organization. Cancer Pain relief: with a guide to opioid availability. 2nd ed. Geneva: World Health Organization; 1996.

Zech D, Grond S, Lynch J, Hertel D, Lehmann K. Validation of World Health Organization Guidelines for cancer pain relief: A 10-year prospective study. Pain. 1995;63(1):65-76.

https://doi.org/10.1016/0304-3959(95)00017-M

Davis MP. Buprenorphine in cancer pain. Support Care Cancer. 2005;13(11):878-87.

https://doi.org/10.1007/s00520-005-0849-9

Evans HC, Easthope SE. Transdermal buprenorphine. Drugs. 2003;63(19):1999-2010.

https://doi.org/10.2165/00003495-200363190-00003

Sittl R. Transdermal buprenorphine in cancer pain and palliative care. Palliat Med. 2006;20 Suppl 1:s25-30.

Skaer TL. Transdermal opioids for cancer pain. Health Qual Life Outcomes. 2006;4:24.

https://doi.org/10.1186/1477-7525-4-24

Zaki PA, Keith DE, Brine GA, Carroll FI, Evans CJ. Ligandinduced changes in surface mu-opioid receptor number: relationship to G protein activation? J Pharmacol Expert Ther. 2000; 292(3):1127-34.

Budd K. Immunosuppressive effects induced by opioid analgesics. Int Monit Reg Anaesth and Pain Management. 2000;14:3-7.

Mercadante S, Ferrera P, Villari P. Is there a ceiling effect of transdermal buprenorphine? Preliminary data in cancer patients. Support Care Cancer. 2007;15(4):441-4.

https://doi.org/10.1007/s00520-006-0169-8

Poulsen Nautrup B, Nuijten MJC. Retrospective analysis of drug utilization patterns in cancer and non-cancer patients treated with transdermal buprenorphine and transdermal fentanyl. Value Health. 2005;8:411-2.

https://doi.org/10.1016/S1098-3015(10)63122-1

Sittl R, Likar R, Nautrup B. Equipotent does of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. Clin. Ther. 2005;27(2):225-37.

https://doi.org/10.1016/j.clinthera.2005.02.012

Ficha técnica de Buprenorfina transdermica Transtec® Grunenthal. 2002.

Bullinham R, McQuay HJ, Porter E, Allen MC, Moore R. Sublingual buprenorphine used postoperatively: ten hour plasma drug concentration analysis. Br J Clin Pharmacol 1982;13(5):665-73.

https://doi.org/10.1111/j.1365-2125.1982.tb01434.x

Sittl R. Buprenorphine transdermal patch: clinical expert report. Germany: Grünenthal GmbH. 2000.

Sittl R, Griessinger N, Likar R. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther. 2003;25(1):150-68.

https://doi.org/10.1016/S0149-2918(03)90019-1

Sacerdote P, Manfredi B, Mantegazza P, Panerai AE. Antinociceptive and immunosuppressive effects of opiate drugs: a structure-related activity study. Br J Pharmacol. 1997;121(4):834-40.

https://doi.org/10.1038/sj.bjp.0701138

Van Loveren, Gianotten N, Hendriksen CF, Schuurman HJ, Van der Laan JW. Assessment of immunotoxicity of buprenorphine. Lab Anim. 1994;28(4):355-63.

https://doi.org/10.1258/002367794780745119

Johnson RE, Fudala PJ, Payne R. Buprenorphine: considerations for pain management. J Pain Symptom Manage. 2005;29(3):297-326.

https://doi.org/10.1016/j.jpainsymman.2004.07.005

Schriek P. Treatment of cancer-related pain with transdermal buprenorphine: a report of three cases. Support Care Cancer. 2004;12(12):882-4.

https://doi.org/10.1007/s00520-004-0695-1

Muriel C y Grupo de Estudio de Opioides de la Sociedad Española de Dolor. Valoración del parche transdérmico de buprenorfina en pacientes con dolor oncológico. Rev Soc Esp Dolor. 2004;11 Supl V:41-8.

Griessinger N, Sittl R, Likar R. Transdermal buprenorphine in clinical practice - post-marketing surveillance study of 13, 179 patients. Cur Med Res Opin. 2005;21(8):1147-56.

https://doi.org/10.1185/030079905X53315

Sorge J, Sittl R. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double blind, placebo controlled study. Clin Ther. 2004; 26(11):1808-20.

https://doi.org/10.1016/j.clinthera.2004.11.008

Böhme K, Likar R. Efficacy and tolerability of a new opioid analgesic formulation, buprenorphine transdermal therapeutic system (TDS), in the treatment of patients with chronic pain. A randomised, double blind, placebocontrolled study. The Pain Clinic. 2003; 15(2):193-202.

https://doi.org/10.1163/156856903321579334

Likar R, Kayser H, Sittl R. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three shortterm clinical trials. Clin Ther. 2006;28(6):943-52.

https://doi.org/10.1016/j.clinthera.2006.06.012

Daha A, Yassen A, Bijl H, Romberg R, Sarton E, Tepema L, et al. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth. 2005;94(6):825-34.

https://doi.org/10.1093/bja/aei145

Kögel B, Christoph T, Straburger W, Friederichs E. Interaction of opioid receptor agonist and antagonist with the analgesic effect of buprenorphine in mice. Eur J Pain. 2005; 9(5):599-611.

https://doi.org/10.1016/j.ejpain.2005.02.002

Jasinki J, Pevnik J, Grifith J. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry. 1978;35(4):501-16.

https://doi.org/10.1001/archpsyc.1978.01770280111012

Mercadante S, Arcuri E. Opioids and renal function. J Pain. 2004;5(1):2-19.

https://doi.org/10.1016/j.jpain.2003.09.007

Kaiko R, Wallenstein S, Rogers A, Grabinski P, Houde R. Narcotics in elderly. Med Clin North Am. 1982;66(5):1071-89.

https://doi.org/10.1016/S0025-7125(16)31383-9